Bridged tricyclic carbamoylpyridone compounds and uses thereof

Patent metadata

Field	Value
Publication number	US-12054496-B2
Application number	US-202318334588-A
Country	US
Kind code	B2
Filing date	Jun 14, 2023
Priority date	Apr 6, 2022
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

The present disclosure relates generally to compounds, of Formula I

Also disclosed are pharmaceutical compositions comprising said compounds and methods of making said compounds. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.

First claim

We claim:

1. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

3. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

4. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

5. The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

6. The compound of a claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

7. The compound of a claim 1 , wherein the compound is:

8. The compound of a claim 1 , wherein the compound is:

9. The compound of a claim 1 , wherein the compound is:

10. The compound of a claim 1 , wherein the compound is:

11. The compound of a claim 1 , wherein the compound is:

12. A pharmaceutical composition comprising a therapeutically effective amount of a compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

13. The pharmaceutical composition of claim 12 , further comprising an additional therapeutic agent.

14. The pharmaceutical composition of claim 13 , wherein the additional therapeutic agent is an anti-HIV agent.

15. The pharmaceutical composition of claim 12 , wherein the pharmaceutical composition is for oral or parenteral administration.

16. The pharmaceutical composition of claim 12 , wherein the compound is:

17. The pharmaceutical composition of claim 12 , wherein the compound is:

18. The pharmaceutical composition of claim 12 , wherein the compound is:

19. The pharmaceutical composition of claim 12 , wherein the compound is:

20. The pharmaceutical composition of claim 12 , wherein the compound is:

21. A kit comprising a compound selected from the group consisting of:

or the pharmaceutically acceptable salt thereof, and instructions for use.

22. A method of treating an HIV infection in a human having the infection, comprising administering to the human a therapeutically effective amount of a compound, or pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

23. The method of claim 22 , further comprising administering to the human a therapeutically effective amount of an additional therapeutic agent.

24. The method of claim 23 , wherein the additional therapeutic agent is an anti-HIV agent.

25. The method of claim 22 , wherein the compound is administered to the human by oral, intravenous, subcutaneous, or intramuscular administration.

26. The method of claim 22 , wherein the compound is:

27. The method of claim 22 , wherein the compound is:

28. The method of claim 22 , wherein the compound is:

29. The method of claim 22 , wherein the compound is:

30. The method of claim 22 , wherein the compound is:

Assignees

• Gilead Sciences Inc

Inventors

• Chu Hang
• Gonzalez Buenrostro Ana Z
• Han Xiaochun
• Hurtley Anna E
• Jiang Lan
• Li Jiayao
• Schwarzwalder Gregg M
• Shivakumar Devleena M
• Von Bargen Matthew J
• Wu Qiaoyin
• Yang Hong

Classifications

• C07B2200/07

  Optical isomers · CPC title

• A61P31/18

  for HIV · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/55

  having seven-membered rings, e.g. azelastine, pentylenetetrazole · CPC title

• C07D498/22 Primary

  in which the condensed system contains four or more hetero rings · CPC title